Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study.
AuthorsTobin, William Oliver
Kinsella, Justin A
Collins, Daniel Ronan
Feeley, Thomas Martin
Murphy, Raymond P
McCabe, Dominick J H
AffiliationDepartment of Neurology, The Adelaide and Meath Hospital/National Children's, Hospital, Tallaght, Dublin, UK.
Blood Platelets/*drug effects/physiology
Blood Specimen Collection/methods
Drug Therapy, Combination
Ischemic Attack, Transient/*blood/drug therapy
Platelet Activation/drug effects
Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
Platelet Function Tests
MetadataShow full item record
CitationBr J Haematol. 2011 Mar;152(5):640-7. doi: 10.1111/j.1365-2141.2010.08539.x. Epub, 2011 Jan 12.
JournalBritish journal of haematology
AbstractEx vivo dipyridamole 'non-responsiveness' has not been extensively studied in ischaemic cerebrovascular disease. Platelet surface marker expression, leucocyte-platelet complex formation and inhibition of platelet function at high shear stress as detected by the PFA-100(R) Collagen-Adenosine-diphosphate (C-ADP) and Collagen-Epinephrine cartridges was assessed in 52 patients within 4 weeks of transient ischaemic attack (TIA) or ischaemic stroke on aspirin, and then 14 d (14 d) and >90 d (90 d) after adding dipyridamole. A novel definition of 'Dipyridamole non-responsiveness' was used. The median C-ADP closure time increased following addition of dipyridamole, remained elevated at 90 d (P /= 0.5), at 14 and 90 d versus baseline. Additional inhibition of platelet function has been detected with the PFA-100 when dipyridamole is added to aspirin. Elevated monocyte-platelet complexes may contribute to ex vivo dipyridamole non-responsiveness.
- Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
- Authors: McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Lawrie AS, Purdy G, Machin SJ, Brown MM
- Issue date: 2005 Aug
- High on-treatment platelet reactivity on commonly prescribed antiplatelet agents following transient ischaemic attack or ischaemic stroke: results from the Trinity Antiplatelet Responsiveness (TRAP) study.
- Authors: Tobin WO, Kinsella JA, Coughlan T, Collins DR, O'Neill D, Murphy RP, Egan B, Tierney S, Feeley TM, McCabe DJ
- Issue date: 2013 Feb
- Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
- Authors: Kinsella JA, Tobin WO, Cox D, Coughlan T, Collins R, O'Neill D, Murphy RP, McCabe DJ
- Issue date: 2013 Oct
- Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
- Authors: Serebruany VL, Malinin AI, Pokov AN, Hanley DF
- Issue date: 2008 Feb
- Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke.
- Authors: Lim ST, Murphy SJX, Murphy SM, Coughlan T, O'Neill D, Tierney S, Egan B, Collins DR, McCarthy AJ, Lim SY, Smith DR, Cox D, McCabe DJH
- Issue date: 2022 Oct 15